Gastrointestinal

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(EXELIXIS) XL184-312 / COSMIC-312A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer TherapyMeyers, Dr BrandonOpen to recruitmentNCT03755791
(Merck) MK-3475-966Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with advanced/Unresectable Biliary Tract CarcinomaKazemi, Dr GhazalehOpen to recruitmentNCT04003636
(AstraZeneca) D910DC00001 / EMERALD-2A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation.Meyers, Dr BrandonRecruitment on hold - COVID-19NCT03847428
(AstraZeneca) D933GC00001 / EMERALD-1A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular CarcinomaZbuk, Dr KevinRecruitment on hold - COVID-19NCT03778957
(CCTG) CO.21 / CHALLENGEA Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients With High Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial (CHALLENGE)Goffin, Dr JohnRecruitment on hold - COVID-19NCT00819208
(UHN) OZM-067 / LuNETA Prospective Single-Arm, Multi-Centre, Study of the Efficacy and Safety of Lutetium-177 Octreotate (Lu-DOTATATE) Treatment with individualized dosimetry in Patients with 68Ga-DOTATATE identified Somatostatin Receptor positive Neuroendocrine TumorsJuergens, Dr RosalynRecruitment on hold - COVID-19NCT02743741
RTOG 1112Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular CarcinomaSwaminath, Dr AnandRecruitment on hold - COVID-19NCT01730937
Download PDF